Riskpilot← Back to searchSign inGet full accessLNH Läkarkonsult AB
ABActiveOrg 5591374029Vanadisvägen 24General medical practice activities · NACE 8621Est. 20171 employees
Revenue 2025
SEK 452K
+33% vs 2024
EBITDA margin
35.6%
+62% vs 2024
Equity ratio
89.5%
Financial strength
Net profit 2025
SEK 128K
+59% vs 2024
| Revenue | SEK 452K | +33% |
| EBITDA | SEK 161K | +62% |
| Net profit | SEK 128K | +59% |
| Total assets | SEK 563K | +28% |
| Equity | SEK 504K | -12% |
| Employees | 1 | — |
Legal name
LNH Läkarkonsult AB
Org number
5591374029
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
5 december 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-11-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet skall vara att tillhandahålla läkarkompetens inom medicin, primärvård och företagshälsovård samt därmed förenlig verksamhet. Bolaget kommer att ordna föreläsningar och utbildningar inom medicin och därmed förenlig verksamhet. Bolaget skall idka handel med värdepapper och fastigheter.
Address
Vanadisvägen 24
Email
loam83@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 611 | 1 404 | 430 | 341 | 452 |
| Staff expenses | — | −18 | −26 | −18 | −16 |
| EBITDA | 365 | −27 | 172 | 99 | 161 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 365 | −27 | 172 | 99 | 161 |
| Net financials | −1 | 0 | 0 | 3 | 3 |
| Profit before tax | 444 | −27 | 172 | 102 | 164 |
| Tax | −96 | — | −31 | −21 | −35 |
| Net profit | 348 | −27 | 141 | 81 | 128 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 617 | 439 | 507 | 440 | 563 |
| Equity | 529 | 503 | 494 | 575 | 504 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 87 | −64 | 13 | −135 | 59 |
| Total debt | 87 | −64 | 13 | −135 | 59 |
EBITDA margin
35.6%
This company
15.8%
Market median
+125% vs market
20212025
Equity ratio
89.5%
This company
38.2%
Market median
+134% vs market
20212025
Return on equity
25.5%
This company
18.4%
Market median
+39% vs market
20212025
Net profit margin
28.4%
This company
8.1%
Market median
+251% vs market
20212025
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-12-01 – 2025-11-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-11-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LNH Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Semret Zekaryas Habte | Deputy Board Member | 0 companies |
| Luwam Habtemariam | Board of Directors | 0 companies |